Dyne Therapeutics Inc [NASDAQ: DYN] gained 10.70% or 1.12 points to close at $11.59 with a heavy trading volume of 14353355 shares.
It opened the trading session at $10.23, the shares rose to $13.5 and dropped to $9.89, the range by which the price of stock traded the whole day. The daily chart for DYN points out that the company has recorded -21.64% loss over the past six months.
If we look at the average trading volume of 2.93M shares, DYN reached to a volume of 14353355 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Dyne Therapeutics Inc [DYN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for DYN shares is $35.09 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on DYN stock is a recommendation set at 1.35. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Bernstein have made an estimate for Dyne Therapeutics Inc shares, keeping their opinion on the stock as Mkt Perform, with their previous recommendation back on June 24, 2025. While these analysts kept the previous recommendation, Raymond James raised their target price to Outperform. The new note on the price target was released on June 11, 2025, representing the official price target for Dyne Therapeutics Inc stock. Previously, the target price had yet another raise to $34, while Oppenheimer analysts kept a Outperform rating on DYN stock.
The Price to Book ratio for the last quarter was 2.32, with the Price to Cash per share for the same quarter was set at 4.81.
Trading performance analysis for DYN stock
Dyne Therapeutics Inc [DYN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 16.95. With this latest performance, DYN shares gained by 38.14% in over the last four-week period, additionally sinking by -21.64% over the last 6 months – not to mention a drop of -50.81% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for DYN stock in for the last two-week period is set at 66.17, with the RSI for the last a single of trading hit 0.96, and the three-weeks RSI is set at 0.84 for Dyne Therapeutics Inc [DYN]. The present Moving Average for the last 50 days of trading for this stock 10.73, while it was recorded at 10.44 for the last single week of trading, and 16.37 for the last 200 days.
Dyne Therapeutics Inc (DYN) Capital Structure & Debt Analysis
According to recent financial data for Dyne Therapeutics Inc. ( DYN), the Return on Equity (ROE) stands at -61.32%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -53.11%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Dyne Therapeutics Inc’s Return on Invested Capital (ROIC) is -60.05%, showcasing its effectiveness in deploying capital for earnings.
Dyne Therapeutics Inc (DYN) Efficiency & Liquidity Metrics
Based on Dyne Therapeutics Inc’s (DYN) latest financial statements, the Debt-to-Equity Ratio is 0.21%, indicating its reliance on debt financing relative to shareholder equity.
Dyne Therapeutics Inc (DYN) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Dyne Therapeutics Inc. (DYN) effectively leverages its workforce, generating an average of -$2161675.39 per employee. The company’s liquidity position is robust, with a Current Ratio of 16.83% and a Quick Ratio of 16.83%, indicating strong ability to cover short-term liabilities.
Dyne Therapeutics Inc [DYN]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for DYN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Dyne Therapeutics Inc go to 2.54%.
An analysis of Institutional ownership at Dyne Therapeutics Inc [DYN]
There are presently around $88.50%, or 88.94%% of DYN stock, in the hands of institutional investors. The top three institutional holders of DYN stocks are: ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC with ownership of 8.02 million shares, which is approximately 8.6697%. FCPM III SERVICES B.V., holding 7.85 million shares of the stock with an approximate value of $$276.86 million in DYN stocks shares; and FCPM III SERVICES B.V., currently with $$260.69 million in DYN stock with ownership which is approximately 7.9853%.
